GlobeNewsWire
08 Dec 2025, 13:00 UTC · 45w ago
Verdict
Headline takes no side. We score SABS +0.60 across two claims — strongly bullish.
+0.60strongly bullish
More positive than 78% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
SAB Biotherapeutics expects to dose the first patient in its Phase 2b SAFEGUARD clinical trial for SAB-142 later this year.
More positive than 98% of claims this week
SAB-142 data presented at ATTD-Asia continues to support its development as a potential best-in-class immunotherapy for delaying T1D progression.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 67% of claims this week
Which stocks this story touches
More positive than 78% of ticker scores this week
The company is presenting clinical data at a major international conference and advancing its lead program SAB-142 into Phase 2b trials.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
2h ago
−23.6%
Price is moving against the score
$3.04 vs $3.98 close before publication (Dec 5) · not market-adjusted
SABS chart →
